Introduction
Pneumocystis pneumonia (PCP) can be observed in both HIV and non-HIV patients including those with hematological malignancies, transplantation, immunosuppression, and dysimmunity and even in immunocompetent people such as severely malnourished infants [1] . The mortality rate remains high in immunocompromised patients and among HIV positive individuals in whom trimethoprim-sulfamethoxazole 65 -90% [8, 9] . Therefore, it is essential to improve the Se levels of these assays for laboratory diagnosis of PCP. On the other hand, molecular biology approaches can detect microorganisms with great Se. However, some parameters of such tests require evaluation, such as the assay variability, comparative analysis of PCR results among different laboratories and the interpretation of results with low positive predictive values [10] . The requirements of further investigation to evaluate the diagnostic parameters of Polymerase Chain Reaction (PCR) techniques have also been noted elsewhere [11, 12] . Several Pneumocystis jirovecii genes have been targeted for the PCR diagnosis of PCP [12] . Among them, the gene encoding for the major surface glycoprotein (MSG) is one of the most abundantly expressed in Pneumocystis , and can consequently increase the PCR diagnostic Se [13] . Moreover, PCR that targets the MSG can detect the highly variable repertoire of the MSG-gene which is composed of 50 -100 different copies in each genome [14, 15] . On the one hand, the most sensitive tests have been PCRs that target MSG and the large subunit mitochondrial ribosomal RNA (mtLSUrRNA) genes [12, 16] . On the other hand, amplifi ed Pneumocystis DNA may indicate the presence of the fungus without clinical confi rmation of pneumonia. Indeed, temporary P. jirovecii colonization has already been reported [17] . Thus, a quantitative PCR (qPCR) has been selected, with the aim of discriminating P. jirovecii colonization from infection [5, 18] . We have opted for a quantitative touch-down real-time PCR (q-TD-MSG-PCR) targeting the MSG of P. jirovecii and equipped with both a Fluorescence Resonance Energy Transfer (FRET) probe detection and an appropriate internal control [5,18 -20] . The chosen method should increase the Se of PCP diagnosis with high specifi city (Sp), predictive values, and low variability, which will allow physicians to monitor response to treatment.
Material and methods
The evaluation of the diagnostic performance of the PCR presented here is in accordance with the standards for reporting diagnostic accuracy (STARD) [21] . A summary of the q-TD-MSG-PCR standardization process is shown in Fig. 1 (Table 1 ). The BAL samples were collected, stained and examined by at least two qualifi ed microscopists, with a total 400 μ l of BAL fl uid analyzed by Fast Giemsa (RAL 555) and 400 μ l observed after Gomori-Grocott staining on cytospin slides.
Quantitative touch-down major surface glycoprotein polymerase chain reaction (q-TD-MSG-PCR)
The extraction of DNA from a pellet obtained from 2 ml of each of the BAL samples was performed with the Qiagen EZ1 DNA tissue kit and the Qiagen Bio Robot EZ1 (Qiagen SA, Courtaboeuf, France) which had an 80% effi ciency. Five micro-liters of the 100 μ l DNA extract solution from each sample were tested with a q-TD-MSG-PCR targeting the MSG of P. jirovecii and the corresponding specifi c primers (1 μ M each). Probes (0.2 μ M each), 5 mM MgCl 2 , and 1 U of uracil-DNA glycosylase were used to obtain a fi nal volume of 20 μ l per capillary tube [5, 19] . Each assay was repeated twice. The mix LightCycler (LC) Fast Start DNA hybridization probes (Roche, Meylan, France) was used with the LightCycler 2.0 (Roche, Meylan, France). Specifi c primers (0.5 μ M each) and probes (0.2 μ M each) that targeted mouse galactose-1-phosphate-uridyl transferase were employed as internal controls [5] . The q-TD-MSG-PCR was carried out with FRET hybridization probes with fl uorescence readings at 640 nm for the Pneumocystis probe and 705 nm for the internal controls. The quantifi cation began after the touchdown step. The standard curve was obtained with plasmids containing 10 4 , 10 3 , 10 2 and 10 1 MSG copies per capillary. The results were expressed as the means of both measures in the number of MSG copies/ml of BAL fl uid. To standardize the PCR for PCP diagnosis, the intra-and inter-assay variability values were assessed. The dynamic range of q-TD-MSG-PCR was evaluated between 10 1 and 10 8 MSG copies of P. jirovecii per capillary. P. jirovecii variants were evaluated by their respective melting peak analyses.
Determination of the cut-offs
For the characterization of the diagnostic variables of the PCR, the cut-off for PCP was determined by both the analysis of the ROC curve and the best addition of Yule ' s Q Coeffi cient and Youden ' s index.
Diagnostic criteria of Pneumocystis pneumonia
Clinically suspected PCP patients . PCP has a broad spectrum of clinical and paraclinical signs [1] . It was suspected when the patient under antibiotic therapy had symptoms of acute respiratory illness with one or more of the following features; fever, dry cough, diffuse interstitial infi ltrates (chest radiography), and ground glass attenuation (tomodensitometry).
Confi rmed PCP patients . The gold standard used in this study was both the clinical suspicion of PCP associated with the presence of P. jirovecii detected by direct microscopic analysis of Giemsa and/or Gomori-Grocott stained samples
Statistical analyses
The Mann-Whitney U test was performed with the different variables to obtain a signifi cant or insignifi cant difference between the suspected and proven PCP groups. For analysis, hematological malignancy and corticoid-treated solid tumor pathology factors were grouped. P value Ͻ 0.05 was considered signifi cant. The Confi dence Interval (95% CI) was evaluated for per cent of data. The diagnostic accuracy (ACC) and precision (PRE) were defi ned as follows:
in which TP ϭ true positive; TN ϭ true negative; P ϭ number of positive and N ϭ number of negative. and/or if microscopic examination was negative, a favorable outcome under specifi c treatment for PCP.
Prophylaxis and treatment
Both the prophylaxis and curative therapy used were in accordance with the usual guidelines for PCP treatment, e.g., (a) trimethoprim-sulfamethoxazole or pentamidine was prescribed for prophylactic purpose and as curative treatment; (b) atovaquone was given as curative treatment in case adverse effects caused by trimethoprim-sulfamethoxazole, and (c) oral or intravenous therapy was given to patients with either mild symptoms or signifi cant hypoxemia. It should be noted that the patients did not systematically receive prophylactic therapy. 
Results
Characteristics in suspected and confi rmed Pneumocystis pneumonia patients Table 1 provides the characteristics of suspected and confi rmed PCP patients. Haematological malignancy, corticoid treated-solid tumor factor ( P ϭ 0.0114) together with neutrophil ( P ϭ 0.0465) and lymphocyte counts ( P ϭ 0.0416) varied signifi cantly between the suspected and confi rmed PCP patients (Mann-Whitney U test). The other factors, such as age and sex, did not signifi cantly differ from one group to another (Table 1) . Among the confi rmed PCP cases, 3/18 patients (16.7%) were HIV positive, 95% CI [6 -40%]. Table 2 presents the clinical and paraclinical data from the suspected (and unconfi rmed) and confi rmed PCP groups. Among the clinically suspected cases, the study revealed: (a) Seventeen patients with infectious (bacterial, viral and fungal) pneumonia other than PCP, (b) three patients with interstitial pneumonia associated with autoimmune disorders, (c) three patients with idiopathic pulmonary fi brosis, (d) two patients with pulmonary arterial hypertension, and (e) 11 patients with other forms of pneumopathy (pulmonary emphysema, bronchopneumonia, bronchorrhea, pneumothorax, progression of broncho-alveolar carcinoma, etc.). Persistent fever and hypoxemia were signifi cantly different from one group to another, as indicated by the Mann-Whitney U test (Table 2 ). The other clinical or paraclinical records did not demonstrate signifi cant differences in the two groups. Table  3 . The q-TD-MSG-PCR was the most sensitive, discriminative and accurate assay in the diagnosis of PCP, while the staining techniques were the most specifi c. The likelihood positive ratio of the selected cut-off was 44 for the q-TD-MSG-PCR-based diagnosis whereas the likelihood negative ratio was zero. Table 3 also highlights both the characteristics of the Gomori-Grocott and Fast Giemsa diagnosis methods used in our study, and the area under the ROC curve obtained for each assay. The results of these laboratory assays are linked to PCP, as refl ected by the Spearman ' s rank correlation coeffi cient (data not shown), the Yule ' s Q coeffi cient (Table 3 ) and the signifi cant differences between the confi rmed and suspected PCP groups (Mann-Whitney U Test; P ϭ 0.0001).
General data from enrolled patients

Characteristics of the laboratory tests used for PCP diagnosis
The characterization of the q-TD-MSG-PCR was continued by: (a) The determination of the intra-and interassay variability values, as shown in Fig. 2A and 2B ; (b) the determination of the dynamic range of the q-TD-MSG-PCR that covered 7 log units, as presented in Fig. 2C ; Fig. 2D ; (d) the diagnostic accuracy as shown in Table 3 ; and (e) the detection of MSG gene variants thanks to analysis of the melting temperature (Tm). One example (Fig. 2E) shows the melting temperatures obtained from three different isolates of P. jirovecii . A given Tm was arbitrarily considered dissimilar if the difference was Ͼ 0.5 ° C. Some of the patients were subjects of surveillance studies from whom two to four BAL samples were collected. In patient 4, who had an intolerance to trimethoprim-sulfamethoxazole, PCR was the earliest assay (Day 0) performed in relation with a PCP relapse. Under treatment pressure P. jirovecii was not microscopically observed with Giemsa and Gomori-Grocott staining performed at Day 27, although numerous MSG copies were measured by PCR. In patients 17 and 18, the staining methods were negative for P. jirovecii trophozoite and cyst detection in BAL fl uids. For this individual, the PCR results were positive despite the pentamidine prophylaxis and the trimethoprim-sulfamethoxazole treatment that had been initiated a week before the BAL fl uid examination. After the episode of clinical severe pneumocystosis, patient 17 had a favorable outcome but thereafter developed multifactor pulmonary fi brosis and died of terminal respiratory failure two weeks later as a result of immunodeficiency caused by treatment of a thoracic neuroblastoma. For patient 18, during an episode of mild pneumocystosis, PCR results were positive and after a week of curative trimethoprim-sulfamethoxazole treatment, a marked decrease in of the pulmonary interstitial infi ltrates was noted in a context of immunodefi ciency due to the treatment of acute myeloid leukemia. Patient 19 suffered from CMV pneumonia, although the clinical evolution was not favorable under CMV-specifi c treatment. For this patient with possible PCP, PCR was positive but the pneumocystosis was not proven due to the lack of a specifi c treatment (see diagnostic criteria). Thus, the data was considered to be indicative of a false positive for the determination of the diagnostic characteristics of the technique under study.
Clinical characteristics of PCP patients with regards to laboratory results
Discussion
In the laboratory diagnosis of PCP, a few technical and biological factors can explain the robustness and reliability of the q-TD-MSG-PCR. Since the same DNA-extraction method was used for each BAL sample, the possible PCR inhibition may be uniform in all the samples since the crossing points of the internal controls had been stable throughout the study. Moreover, PCR inhibition due to the DNA extraction method can be very low, as no false negative results were observed. Thus, an absolute quantifi cation of MSG gene copies may be done. The chosen touch-down phase may increase the analytical Se and Sp of the assay [19, 22] . Then, the FRET probes utilized may increase the Sp of PCP diagnosis with no loss of analytical Se. Finally, the q-TD-MSG-PCR can detect the highly variable repertoire of the MSG-gene [14, 15] . This variability was overcome due to a base degenerated-MSG primer and probe. This phenomenon is reflected in the melting peak analysis that allowed us to appreciate the genetic variability of P. jirovecii isolates. Table 3 ). The cut-off with 100% Sp was 66.800 MSG copies/ml of BAL fl uid. The discriminative power of the test was very good since the area under the ROC curve was 0. For a fi ne analysis of this variability, MSG-gene sequencing of the isolates may be necessary [14] . The approximate genetic variability may account for the q-TD-MSG-PCR high Se and refl ects the nature of the P. jirovecii variants in human samples. The q-PCR can evaluate the MSG copies of P. jirovecii , in contrast with the staining techniques that detect the fungus. Indeed, in one BAL sample from patient 4, who was under trimethoprim-sulfamethoxazole treatment, numerous MSG copies were quantifi ed although the fungus was not identifi ed on different slides. Although a binary-PCR result may be useful for medical screening, q-PCR is required for laboratory diagnosis, as well as for the determination of an optimal cut-off value for PCP, as a result of the fact that a PCR-based diagnosis can have low positive predictive value [5, 10, 16, 20] . In semi or quantitative PCR, low-predictive values have been obtained when the gold standard is a laboratory assay [20, 23] . From the practical point of view, an infection cutoff discriminates between suspected and confi rmed PCP patients. This has also been found between the patients with low and high probability of PCP by another quantitative PCR that targets the mtLSUrRNA gene of P. jirovecii [16] . Then, the rationale for laboratory diagnosis may be the determination of the cut-off value for PCP, which has to take into account the patient ' s clinical, immunological and radiological data. A colonized immunocompetent person or a hospitalized-HIV-infected patient may not present clinical manifestation of PCP [24] . The infection cut-off can discriminate between Pneumocystis colonization and infection in an appropriate clinical context. The high value of the area under the ROC curve supports this observation.
In our study, the analysis of the ROC curve suggests a close relationship among the diagnostic Se, Sp and cut-off value of a test. Such relationship has also been reported by Larsen et al . [18] who employed the same type of PCR, except that DNA was extracted from oral washes of HIVinfected PCP patients and from BAL samples. In the study of Alanio et al . [16] with another quantitative PCR system, this kind of relationship was also found with the lower and the upper cut-off values. Therefore, a combination of a quantifi cation procedure and an optimal cut-off may lead to a 100% diagnostic Se with a good Sp as seen in the present study. P. jirovecii can transiently colonize healthy people since this microorganism is usually complete cleared [17] . In immunocompromised, as well as in healthy people, the colonization by Pneumocystis may act as a reservoir for infection and exacerbate other pulmonary diseases [13, 25, 26] . Immunocompromised patients, with no clinical signs of pneumonia and a positive q-TD-MSG-PCR test, can be assumed to be colonized by P. jirovecii , and may be monitored by the serum (1 → 3)-beta-D-glucan content for an eventual PCP [8, 9] . Immunocompromised patients, with both clinical signs of pneumonia and a positive q-TD-MSG-PCR test, can be assumed to be infected by P. jirovecii . Our results suggest that the notions of infection and colonization by P. jirovecii are relative and may depend on the PCP clinical manifestation, the patient ' s immune status, associated co-infections, the level of intolerance to treatment and the extent of vital risk. This was observed in patient 17, affected by a neuroblastoma associated with treated PCP before the PCR test, and in the studies by Larsen et al . [18, 19] . Such high diagnostic sensitivity with a good Predictive Positive Value may also be useful in patients with hematological malignancies and possible low fungus load associated with PCP, as observed in patient 18, who had acute myeloid leukemia. In some cases, the improvement of clinical and paraclinical signs of pneumonia under specifi c therapy can provide the answer in association with positive q-TD-MSG-PCR data. The q-TD-MSG-PCR method may have one of the highest Se of all laboratory assays used to diagnose PCP (see Table 5 ) [5, 12, 19] .
The high negative predictive value of q-TD-MSG-PCR suggests that a negative result from BAL samples rules out the possibility of Pneumocystis pneumonia, as observed in our study and others [20] . Comparable diagnostic Se and Sp for PCP have been observed with this test in various laboratories and may represent a path towards the standardization and optimizations of PCR assays [5, 16, 19, 20] . The inter-laboratory results with PCR are comparable, in spite of the use of different internal controls and software [5, 19] . This path towards standardization has been reached with one PCR technique, i.e., q-TD-MSG-PCR. However, the recent paper by White et al . [27] suggests that this can be achieved with several types of PCR. This step should also be crossed with multiple quantitative Pneumocystis PCR [16,23,28 -30] . In the present study, we briefl y compared the quantitative PCR with the crossing point data from a commerciallyavailable kit that targets mtLSUrRNA gene of P. jirovecii (FXGTM: RESP (Asp ϩ ); Myconostica Ltd (Manchester, UK)) with a good correlation ( r ϭ 0.959; P ϭ 0.0006, data not shown). Only one major difference was observed since FXGTM-Pneumocystis PCR result was negative in the case of a PCP relapse in patient 4 (data not shown). To our knowledge, the consensus defi nitions for the biological diagnosis of PCP do not exist yet. Quantitative PCR might be admitted in this future consensus as a diagnostic tool, together with other direct or indirect microscopic observations. When an immunocompromised patient is followed up because of a high risk for PCP, an optimally standardized q-PCR with high Se is useful to quantify DNA from P. jirovecii . In confi rmed PCP patients, the morbidity may be decreased thanks to q-PCR and early specifi c treatment. Moreover, the high negative predictive value of q-PCR may avoid useless treatment in suspected patients.
Although it is well known that the clinical signs are not specifi c to PCP, we noted that both persistent fever and hypoxemia may have signifi cantly different values between suspected-and confi rmed-PCP groups of patients. In our study, the main risk factor for Pneumocystis pneumonia was hematological malignancies and corticoid treated-solid tumor as has been reported elsewhere [31] . This may be due to the absence of primary prophylaxis and intensive therapy against hematological forms of cancer. Likewise, our lymphocyte count data support the fi nding that lymphopenia is a risk factor for PCP [32] . The course of PCP and the mortality rate were not favorable in HIV-negative patients, as has been reported in other studies [33] . However, Fisk et al . [3] noted that this might be true for HIV-infected patients in whom trimethoprim-sulfamethoxazole treatment has failed. We did not observe such results since our study included only three HIV-positive patients with PCP. Under highly active antiretroviral therapy, the overall mortality rate among those patients was 11.3% but this rate varied in terms of the disease severity, ranging from 3.7 -49.1% [31] . The highmortality rate and/or intolerance to PCP treatment can justify the use of a q-PCR with high Se and high PPV.
Conclusion
The q-TD-MSG-PCR has a good diagnostic value independent of the disease prevalence and is rather fast. Quantitative PCR targeting MSG gene of P. jirovecii could be used as an early, discriminating, and accurate tool to diagnose PCP even in cases of low Pneumocystis load. Used in association with a very early specifi c treatment, it may help decrease morbidity.
